Market Access Strategies for the Global Healthcare Environment mktxs linkedin 1-908-864-4090

Budget impact model on high treatment costs related to inappropriate dosing


Our client wanted to communicate the budge impact of biologics used to treat immunologic diseases to Payers who are concerned about costs related to off-label dosing of expensive drugs

Out-of-pocket burden and the impact/barrier to cost sharing of care in mCRC


Our client wanted to identify the patient population at risk for high out-of-pocket spending and quantify the amount incurred over a calendar year of treatment

Orphan Disease Market Opportunity Assessment


A pharmaceutical market leader wanted to evaluate opportunity in pulmonary arterial hypertension (PAH) as an orphan drug in the face of:

  • A market with the current standard of care driven by with generic therapies
  • Low incidence with high morbidity/mortality rates
  • High treatment cost